High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study | Zendy

Christiane Drechsler | Zendy; Pieter Evenepoel | Zendy; Marc G. Vervloet | Zendy; C. Wanner | Zendy; M. Ketteler | Zendy; Nicole Marx | Zendy; J. Floege | Zendy; Friedo W. Dekker | Zendy; Vincent Brandenburg | Zendy

Open Access

High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study

Author(s) -

Christiane Drechsler,

Pieter Evenepoel,

Marc G. Vervloet,

C. Wanner,

M. Ketteler,

Nicole Marx,

J. Floege,

Friedo W. Dekker,

Vincent Brandenburg

Publication year - 2014

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfu301

Subject(s) - sclerostin , medicine , dialysis , hazard ratio , prospective cohort study , endocrinology , kidney disease , proportional hazards model , cohort study , cohort , confidence interval , wnt signaling pathway , biochemistry , chemistry , gene

Sclerostin is a Wnt pathway antagonist regulating osteoblast activity and bone turnover, and it plays a role in cardiovascular calcification processes. Previous findings indicate that sclerostin regulation is disturbed in chronic kidney disease (CKD). The aim of this study was to assess the association of circulating sclerostin levels with mortality in dialysis patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research